SwePub
Sök i LIBRIS databas

  Extended search

onr:"swepub:oai:DiVA.org:oru-97744"
 

Search: onr:"swepub:oai:DiVA.org:oru-97744" > First characterisat...

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist
  • Al-Maslamani, MunaHamad Medical Corporation, Doha, Qatar (author)

First characterisation of antimicrobial susceptibility and resistance of Neisseria gonorrhoeae isolates in Qatar, 2017-2020

  • Article/chapterEnglish2022

Publisher, publication year, extent ...

  • 2022-03-02
  • PLOS,2022
  • printrdacarrier

Numbers

  • LIBRIS-ID:oai:DiVA.org:oru-97744
  • https://urn.kb.se/resolve?urn=urn:nbn:se:oru:diva-97744URI
  • https://doi.org/10.1371/journal.pone.0264737DOI

Supplementary language notes

  • Language:English
  • Summary in:English

Part of subdatabase

Classification

  • Subject category:ref swepub-contenttype
  • Subject category:art swepub-publicationtype

Notes

  • Funding agency:Biomedical Research Program
  • Limited data are available regarding antimicrobial resistance in Neisseria gonorrhoeae strains circulating in WHO Eastern Mediterranean Region (EMR). We investigated the antimicrobial susceptibility/resistance of N. gonorrhoeae isolates to five antimicrobials (ceftriaxone, azithromycin, ciprofloxacin, tetracycline, and benzylpenicillin) currently or previously used for gonorrhoea treatment in Qatar, 2017-2020. Minimum inhibitory concentrations (MICs; mg/L) of antimicrobials were determined using Etest on gonococcal isolates collected during January 1, 2017-August 30, 2020 at Hamad Medical Corporation, a national public healthcare provider. During 2017-2020, resistance in isolates from urogenital sites of 433 patients was 64.7% (95% CI: 59.5-69.6%; range: 43.9-78.7%) for ciprofloxacin, 50.7% (95% CI: 45.3-56.1%; range: 41.3-70.4%) for tetracycline, and 30.8% (95% CI: 26.3-35.6%; range: 26.7-35.8%) for benzylpenicillin. Percentage of isolates non-susceptible to azithromycin was 4.1% (95% CI: 2.0-7.4%; range: 2.7-4.8%) and all (100%) isolates were susceptible to ceftriaxone. Two (1.6%) isolates from 2019 and one (2.2%) isolate from 2020 had high-level resistance to azithromycin (MIC≥256 mg/L). Overall, 1.0% (4/418) of isolates had a ceftriaxone MIC of 0.25 mg/L, which is at the ceftriaxone susceptibility breakpoint (MIC≤0.25 mg/L). Treatment with ceftriaxone 250 mg plus azithromycin 1 g can continuously be recommended for gonorrhoea therapy in Qatar. Continued quality-assured gonococcal AMR surveillance is warranted in EMR.

Subject headings and genre

Added entries (persons, corporate bodies, meetings, titles ...)

  • Elmagboul, Emad Bashier IbrahimHamad Medical Corporation, Doha, Qatar; Infectious Diseases Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar (author)
  • Puthiyottil, AslamHamad Medical Corporation, Doha, Qatar (author)
  • Chemaitelly, HiamInfectious Diseases Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar (author)
  • Varghese, Manoj KizhakkepeedikayilHamad Medical Corporation, Doha, Qatar (author)
  • Al Romaihi, Hamad EidMinistry of Public Health, Doha, Qatar (author)
  • Al-Thani, Mohamed H.Ministry of Public Health, Doha, Qatar (author)
  • Al Khal, AbdullatifHamad Medical Corporation, Doha, Qatar (author)
  • Unemo, Magnus,1970-Örebro universitet,Institutionen för medicinska vetenskaper,Region Örebro län,Faculty of Medicine and Health, WHO Collaborating Centre for Gonorrhoea and Other Sexually Transmitted Infections, National Reference Laboratory for Sexually Transmitted Infections, Department of Laboratory Medicine, Örebro University, Örebro, Sweden; Institute for Global Health, University College London, London, United Kingdom(Swepub:oru)muo (author)
  • Abu-Raddad, Laith J.Infectious Diseases Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar; World Health Organization Collaborating Centre for Disease Epidemiology Analytics on HIV/AIDS, Sexually Transmitted Infections, and Viral Hepatitis, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar; Department of Population Health Sciences, Weill Cornell Medicine, Cornell University, New York City, New York, United States of America; Department of Public Health, College of Health Sciences, Member of QU Health, Qatar University, Doha, Qatar (author)
  • Hamad Medical Corporation, Doha, QatarHamad Medical Corporation, Doha, Qatar; Infectious Diseases Epidemiology Group, Weill Cornell Medicine-Qatar, Cornell University, Qatar Foundation-Education City, Doha, Qatar (creator_code:org_t)

Related titles

  • In:PLOS ONE: PLOS17:31932-6203

Internet link

Find in a library

  • PLOS ONE (Search for host publication in LIBRIS)

To the university's database

  • 1 of 1
  • Previous record
  • Next record
  •    To hitlist

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Close

Copy and save the link in order to return to this view